Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 8/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709124 | 0.87 | ALOX5AP (0.35) | RET | |
| SCHEMBL16709120 | 0.85 | CSNK1E (0.36) | CSNK1ERETCSNK1DJAK2JAK1 | |
| SCHEMBL16711392 | 0.83 | CSNK1E (0.40) | CSNK1ERETGPR119CSNK1DNR1H2 | |
| SCHEMBL16709116 | 0.81 | KAT5 (0.35) | RETGPR119NR1H2NR1H3 | |
| SCHEMBL16709131 | 0.75 | CSNK1E (0.36) | CSNK1ECSNK1D | |
| SCHEMBL16709129 | 0.74 | CSNK1E (0.44) | CSNK1ECSNK1D | |
| SCHEMBL16709126 | 0.74 | CNR1 (0.36) | — | |
| SCHEMBL16709119 | 0.73 | KAT5 (0.35) | RETGPR119NR1H2NR1H3 | |
| SCHEMBL16711421 | 0.73 | CSNK1E (0.39) | CSNK1EGPR119CSNK1DNR1H2NR1H3 | |
| SCHEMBL16709101 | 0.72 | CSNK1E (0.36) | CSNK1EGPR119CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | BTK 1624/4885CSNK1E 1/4885RET 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.